- Conditions
- ADHD, Bipolar Disorder
- Interventions
- methylphenidate HCl (Concerta)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 169
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 45
- States / cities
- Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
- Conditions
- ADHD
- Interventions
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- LDX Treatment
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
- Interventions
- Centanafadine XR
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 16
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Adhansia XR, Concerta
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Beverly Hills, California • Cromwell, Connecticut + 31 more
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- PDC-1421 Capsule
- Drug
- Lead sponsor
- BioLite, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Attention Deficit Hyperactivity Disorder, Substance Use Disorder
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 15 Years to 30 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Music-Based Binaural Beats Stimulation, Music Listening Without Binaural Beats
- Behavioral
- Lead sponsor
- California State University, San Bernardino
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Bernardino, California
- Conditions
- Smoking, Withdrawal Nicotine, ADHD
- Interventions
- Cigarette smoking, Abstinence
- Behavioral
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Santa Ana, California
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Vayarin®, Placebo
- Other
- Lead sponsor
- Enzymotec
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Marietta, Georgia • Mount Kisco, New York • New York, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Lisdexamfetamine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- PRC-063, lisdexamfetamine dimesylate, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- CTN SR, Matching placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 1 more
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism, ADHD - Attention Deficit Disorder With Hyperactivity, ADHD, ASD, Alcohol Abuse/Dependence, Alcohol Addiction, Alcohol and Other Drug Use Disorders, Alcohol and Other Substance Use Prevention, Gambling Addiction, Gambling Disorder, Sex Abuse, Sex Behavior, Sex Crimes, Sex Disorder, Sex Disorders, Gender Dysphoria, Adult, Eating Behavior Disorders, Narcotic-Related Disorders, Narcotic Addiction, Narcissism, Psychiatric Disorder, Psychedelic Effects in Healthy Volunteers, Psychedelic Experiences, Psychedelic Drug Dependence, Marijuana Use Disorder, Marijuana Abuse and Dependence, Smoking (Tobacco) Addiction, Smoking Among Youth, Smoking Abstinence, Abstinence, Sex, Opiate Substitution Treatment, Opioid Abuse (Disorder), Opioid Abuse and Addiction, Cocaine Abuse, MDMA ('Ecstasy'), Addiction Disorders, Homeless and Low Incomes People, Refugees, Homelessness, Reliability and Validity, Anger Problems, Child Abuse, Sexual
- Interventions
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Behavioral
- Lead sponsor
- Veterans Recovery Network Inc.
- Other
- Eligibility
- 17 Years to 99 Years
- Enrollment
- 1,000,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2045
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Cocaine-Related Disorders, Substance-Related Disorders
- Interventions
- Methylphenidate
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 21 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- ADHD
- Interventions
- ADHD Therapy, Control Therapy
- Device
- Lead sponsor
- Lumos Labs, Inc.
- Industry
- Eligibility
- 22 Years to 55 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Garden Grove, California • Sacramento, California + 10 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Digital Treatment
- Other
- Lead sponsor
- Akili Interactive Labs, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Garden Grove, California • Lauderhill, Florida + 11 more
- Conditions
- ADHD, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
- Interventions
- MG01CI (1400 mg), placebo
- Drug
- Lead sponsor
- Alcobra Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 18
- States / cities
- Gainesville, Florida • South Miami, Florida • Libertyville, Illinois + 15 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- NAT electroencephalography (EEG) test
- Other
- Lead sponsor
- Think Now Incorporated
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Berkeley, California • Los Angeles, California • Portland, Oregon
- Conditions
- Attention Deficit Hyperactivity Disorder, ADHD
- Interventions
- Modafinil
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Lafayette, California • Northridge, California + 15 more
- Conditions
- Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
- Interventions
- Dyanavel XR, Placebo
- Drug
- Lead sponsor
- Rochester Center for Behavioral Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Rochester Hills, Michigan
- Conditions
- Attention Deficit Disorder With Hyperactivity (ADHD)
- Interventions
- ALKS 7290, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Chino, California • Clermont, Florida + 20 more
- Conditions
- Attention Deficit Disorder
- Interventions
- Extended-release bupropion hydrochloride
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more